Drug intelligence / Profile preview

Gemox + PD-1 antibody

Development stage: Unknown
Lead developer: Simcere Zaiming
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral, Intramuscular

Overview

Gemox + PD-1 antibody is a combination immunochemotherapy regimen consisting of gemcitabine, oxaliplatin, and an anti-PD-1 monoclonal antibody. This combination leverages both cytotoxic chemotherapy and immune checkpoint inhibition to treat various advanced cancers. The chemotherapy component (Gemox) directly kills cancer cells while potentially enhancing tumor antigen presentation, while the PD-1 antibody blocks the PD-1/PD-L1 immune checkpoint pathway, restoring T-cell function and enhancing anti-tumor immune responses.

Other names: P-GEMOX + anti-PD-1 antibodyGEMOX + toripalimabGEMOX + camrelizumab

Targets

DNAPDCD1 (Programmed cell death protein 1 receptor)RNR (Ribonucleotide reductase)

Beyond the preview

Go deeper on Gemox + PD-1 antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gemox + PD-1 antibody.

Explore the full profile